Obesity, secondary (hypogonadotropic) hypogonadism (SH), sleep disorders (such as Obstructive Sleep Apnoea [OSA]) and Type 2 Diabetes Mellitus (T2DM) in men have complex interlinks both with respect to mutual aetiopathogenesis as well as therapeutics.
Correction of the attendant hypogonadism in obese men may serve to break this link and have beneficial effects beyond restoration of normal sexual function. Male Obesity-associated Secondary Hypogonadism (MOSH) should be regarded as a distinct clinical entity and subtype of SH. A high index of suspicion for the presence of MOSH must be maintained by clinicians when assessing obese men. The pathogenesis of MOSH remains incompletely understood. Furthermore, the optimal management of MOSH and its associated sequelae will require long-term prospective studies that in turn will inform the development of future clinical guidelines for this important and prevalent condition.
Written by:
Aftab SS, Kumar S, Barber T. Are you the author?
Division of Metabolic and Vascular Health, Warwick Medical School, The University of Warwick, Clinical Sciences Research Laboratories, Clinical Sciences Building, University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX, UK.
Reference: Clin Endocrinol (Oxf). 2012 Nov 3. Epub ahead of print.
doi: 10.1111/cen.12092
PubMed Abstract
PMID: 23121123
UroToday.com Androgen Deficiency Section
